Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans
about
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsManagement of antiangiogenic therapy-induced hypertension.Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1Novel tyrosine kinase signaling pathways: implications in vascular remodeling.Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.The effect of salsalate therapy on endothelial function in a broad range of subjects.Cardiovascular toxicity of tyrosine kinase inhibitors.Endothelial dysfunction and vascular disease - a 30th anniversary update.The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.Ebselen does not improve oxidative stress and vascular function in patients with diabetes: a randomized, crossover trial.A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.Cardio-Oncology: mechanisms of cardiovascular toxicity.Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.
P2860
Q33803564-FA113DE1-E784-4F36-9CA8-A36A39E2BFE4Q36170252-AC9A8BEC-D683-488A-9D08-B1289BE87A46Q36627125-0A2D1D96-D036-4C53-AD9D-C0D2E8626533Q36720089-AB49AB92-0A39-46EA-8DC5-DA75B94B7903Q36751861-AE717370-A0FD-4C0A-9638-F5AF82FFD2A5Q37648486-3EDD1A5D-23D4-4D16-8E01-BAAB4D85167BQ38096429-3D5D9328-9BD1-45BF-85DC-9E842B018751Q38680112-F86CC417-493F-405D-94F0-F684BE89A2EAQ38925714-B8BEE66E-FF3D-4D70-B3D4-3724AEA00302Q41773428-228FDC77-A608-4514-A36F-E5226E3BA5C6Q45343619-0715DA92-5B2D-460D-850F-CEDF1464E35FQ47980265-CCA3330A-7934-45A0-AD5B-5BE5586F8A5CQ48109228-0B432749-208C-482B-9195-63D4B5838BF2Q49568718-F5B54C3A-BD87-47FA-8026-E2ADC465F0CD
P2860
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Contrary effects of the recept ...... ic oxide elaboration in humans
@ast
Contrary effects of the recept ...... ic oxide elaboration in humans
@en
type
label
Contrary effects of the recept ...... ic oxide elaboration in humans
@ast
Contrary effects of the recept ...... ic oxide elaboration in humans
@en
prefLabel
Contrary effects of the recept ...... ic oxide elaboration in humans
@ast
Contrary effects of the recept ...... ic oxide elaboration in humans
@en
P2093
P2860
P1433
P1476
Contrary effects of the recept ...... ic oxide elaboration in humans
@en
P2093
Erica L Mayer
Harold J Burstein
Joshua A Beckman
Keri Hannagan
Maria A Rupnick
Nesreen S Ismail
Susan M Dallabrida
Whitney M Redline
P2860
P356
10.1161/HYPERTENSIONAHA.110.168120
P407
P577
2011-04-11T00:00:00Z